内容紹介
Summary
Background: As the aging of the Japanese population progresses, the administration of postoperative adjuvant chemotherapy(AC)to the elderly is also expected to increase. Objective: To examine the characteristics of AC in cases of colorectal cancer among elderly people aged over 75 years. Patients: Forty-eight cases of colorectal cancer patients who received AC. Methods: The clinicopathological factors, including 14 patient-related factors, 6 operation-related factors, and 2 AC-related factors, as well as the long-term outcomes, were compared between the elderly group of patients aged over 75 years(group O, 12 cases)and the non-elderly group(group Y, 36 cases). Results: Significant differences were observed between groups in neutrophil count(p=0.044), operation time(p=0.044), AC regimen(p=0.006), and administration completion status(p=0.046). Compared to group Y, a higher proportion of oral drug alone(92% vs 39%)and completion rate of the initial setting dose(75% vs 39%)were observed in group O. There was no significant difference in the 2-year disease-free survival rate. Conclusion: Oral preparations of AC may be useful from the viewpoint of tolerability in the elderly.
要旨
背景: 癌患者の高齢化に伴い,高齢者大腸癌患者への術後補助化学療法(adjuvant chemotherapy: AC)適用増加が予想される。目的: 75歳以上の高齢者大腸癌AC症例における特徴を検討する。対象: ACを導入したpStage ⅢおよびハイリスクpStageⅡ大腸癌48例。方法: 「75歳以上の高齢者群(O群)12例」と「75歳未満の非高齢者群(Y群)36例」の2群間における臨床病理学的因子: 患者関連14因子,手術関連6因子,AC関連2因子を比較した。また,2群間の長期成績を比較した。結果: 2群間でAC導入前好中球数(p=0.044),手術時間(p=0.044),AC適用レジメン(p=0.006),投与完遂状況(p=0.046)に有意差を認めた。O群はY群と比較して経口剤単独の割合が高く(92 vs 39%),初期設定量での完遂率も高かった(75 vs 39%)。2年無再発生存率は2群間に有意差を認めなかった。結語: 高齢者における経口製剤でのACは,忍容性の面から有用であると考えられる。
目次
Background: As the aging of the Japanese population progresses, the administration of postoperative adjuvant chemotherapy(AC)to the elderly is also expected to increase. Objective: To examine the characteristics of AC in cases of colorectal cancer among elderly people aged over 75 years. Patients: Forty-eight cases of colorectal cancer patients who received AC. Methods: The clinicopathological factors, including 14 patient-related factors, 6 operation-related factors, and 2 AC-related factors, as well as the long-term outcomes, were compared between the elderly group of patients aged over 75 years(group O, 12 cases)and the non-elderly group(group Y, 36 cases). Results: Significant differences were observed between groups in neutrophil count(p=0.044), operation time(p=0.044), AC regimen(p=0.006), and administration completion status(p=0.046). Compared to group Y, a higher proportion of oral drug alone(92% vs 39%)and completion rate of the initial setting dose(75% vs 39%)were observed in group O. There was no significant difference in the 2-year disease-free survival rate. Conclusion: Oral preparations of AC may be useful from the viewpoint of tolerability in the elderly.
要旨
背景: 癌患者の高齢化に伴い,高齢者大腸癌患者への術後補助化学療法(adjuvant chemotherapy: AC)適用増加が予想される。目的: 75歳以上の高齢者大腸癌AC症例における特徴を検討する。対象: ACを導入したpStage ⅢおよびハイリスクpStageⅡ大腸癌48例。方法: 「75歳以上の高齢者群(O群)12例」と「75歳未満の非高齢者群(Y群)36例」の2群間における臨床病理学的因子: 患者関連14因子,手術関連6因子,AC関連2因子を比較した。また,2群間の長期成績を比較した。結果: 2群間でAC導入前好中球数(p=0.044),手術時間(p=0.044),AC適用レジメン(p=0.006),投与完遂状況(p=0.046)に有意差を認めた。O群はY群と比較して経口剤単独の割合が高く(92 vs 39%),初期設定量での完遂率も高かった(75 vs 39%)。2年無再発生存率は2群間に有意差を認めなかった。結語: 高齢者における経口製剤でのACは,忍容性の面から有用であると考えられる。